Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770-18. doi: 10.1128/AAC.00770-18. [Epub ahead of print]

PMID:
30012767
2.

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial.

Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2018 Jun 29. doi: 10.1164/rccm.201712-2524OC. [Epub ahead of print]

PMID:
29954183
3.

Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.

Velásquez GE, Davies GR, Mitnick CD.

Int J Tuberc Lung Dis. 2018 May 1;22(5):473-474. doi: 10.5588/ijtld.18.0210. No abstract available.

PMID:
29663947
4.

Time to revise WHO-recommended definitions of MDR-TB treatment outcomes.

Lange C, van Leth F, Mitnick CD, Dheda K, Günther G.

Lancet Respir Med. 2018 Apr;6(4):246-248. doi: 10.1016/S2213-2600(18)30104-8. No abstract available.

PMID:
29595505
5.

Has compassionate use ever sunk a drug?

McAnaw S, Rodriguez CA, Muller A, Mitnick C, Horsburgh CR.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):119-120. doi: 10.5588/ijtld.17.0793. No abstract available.

PMID:
29506605
6.

Feasibility and yield of screening for non-communicable diseases among treated tuberculosis patients in Peru.

Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):86-92. doi: 10.5588/ijtld.17.0381.

PMID:
29297431
7.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

8.

Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.

Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD.

Clin Infect Dis. 2017 Oct 15;65(8):1364-1370. doi: 10.1093/cid/cix556.

PMID:
29017248
9.

Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01524-17. doi: 10.1128/AAC.01524-17. Print 2017 Sep. No abstract available.

10.

Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.

Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD.

Int J Tuberc Lung Dis. 2017 Aug 1;21(8):894-901. doi: 10.5588/ijtld.16.0850.

PMID:
28786798
11.

Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.

Guglielmetti L, Varaine F, Huerga H, Bonnet M, Rich ML, Mitnick CD.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700598. doi: 10.1183/13993003.00598-2017. Print 2017 Jul. No abstract available.

12.

Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis.

Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB.

ERJ Open Res. 2017 Jul 12;3(3). pii: 00026-2017. doi: 10.1183/23120541.00026-2017. eCollection 2017 Jul.

13.

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.

Varaine F, Guglielmetti L, Mitnick CD.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1490-1491. doi: 10.1164/rccm.201705-0988LE. No abstract available.

PMID:
28715258
14.

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00038-17. doi: 10.1128/AAC.00038-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

15.

(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.

Milstein M, Brzezinski A, Varaine F, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):18-23. doi: 10.5588/ijtld.16.0039. Review.

PMID:
28240568
16.

Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.

Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):8-12. doi: 10.5588/ijtld.16.0066.

PMID:
28240566
17.

Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting.

Horsburgh CR, Rusen ID, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):1-3. doi: 10.5588/ijtld.16.0568. No abstract available.

PMID:
28240564
18.

Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e00069-17. doi: 10.1128/AAC.00069-17. Print 2017 Mar. No abstract available.

19.

Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis.

Nourzad S, Jenkins HE, Milstein M, Mitnick CD.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):6-11. doi: 10.5588/ijtld.16.0110.

20.

Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

Kendall EA, Cohen T, Mitnick CD, Dowdy DW.

Int J Infect Dis. 2017 Mar;56:185-189. doi: 10.1016/j.ijid.2016.12.010. Epub 2016 Dec 19. Review.

21.

Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru.

Tierney DB, Milstein MB, Manjourides J, Furin JJ, Mitnick CD.

Glob Pediatr Health. 2016 Oct 26;3:2333794X16674382. eCollection 2016.

22.

Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management.

Guglielmetti L, Le Dû D, Fréchet-Jachym M, Mitnick C.

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1170-1171. No abstract available.

PMID:
27797614
23.

Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.

Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. No abstract available.

PMID:
27739887
24.

The Use of Bovine Collagen-glycosaminoglycan Matrix for Atypical Lower Extremity Ulcers.

Garwood CS, Kim PJ, Matai V, Steinberg JS, Evans KK, Mitnick CD, Attinger CE.

Wounds. 2016 Sep;28(9):298-305.

PMID:
27701125
25.

Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6766-6773. doi: 10.1128/AAC.00632-16. Print 2016 Nov. Erratum in: Antimicrob Agents Chemother. 2017 Feb 23;61(3):.

26.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P; Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment.

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016. Epub 2016 Sep 1.

27.

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.

Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD.

BMC Infect Dis. 2016 Aug 27;16(1):453. doi: 10.1186/s12879-016-1790-x.

28.

A Bayesian response-adaptive trial in tuberculosis: The endTB trial.

Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L.

Clin Trials. 2017 Feb;14(1):17-28. doi: 10.1177/1740774516665090. Epub 2016 Sep 23.

PMID:
27559021
29.

Building a Multidisciplinary Hospital-Based Wound Care Center: Nuts and Bolts.

Kim PJ, Attinger CE, Steinberg JS, Evans KK, Akbari C, Mitnick CD, Johnson-Arbor KK, Singh B.

Plast Reconstr Surg. 2016 Sep;138(3 Suppl):241S-7S. doi: 10.1097/PRS.0000000000002648.

PMID:
27556768
30.

What Heals Hidradenitis Suppurativa: Surgery, Immunosuppression, or Both?

Falola RA, DeFazio MV, Anghel EL, Mitnick CD, Attinger CE, Evans KK.

Plast Reconstr Surg. 2016 Sep;138(3 Suppl):219S-29S. doi: 10.1097/PRS.0000000000002671. Review.

PMID:
27556765
31.

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F; RESIST-TB (Research Excellence to Stop TB Resistance) and GDI (Global Drug Resistant TB Initiative).

PLoS One. 2016 May 25;11(5):e0155968. doi: 10.1371/journal.pone.0155968. eCollection 2016. Review.

32.

Presumptive treatment of multidrug-resistant tuberculosis in household contacts.

Parr JB, Rich ML, Keshavjee S, Franke MF, Mitnick CD, Bayona J, Becerra MC.

Int J Tuberc Lung Dis. 2016 Mar;20(3):370-5. doi: 10.5588/ijtld.15.0433.

PMID:
27046719
33.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

34.

Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis.

Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS One. 2016 Mar 29;11(3):e0151724. doi: 10.1371/journal.pone.0151724. eCollection 2016.

35.

Using existing data to illustrate--and close--the gap in access to new anti-tuberculosis drugs.

Mitnick C, van den Hof S.

Int J Tuberc Lung Dis. 2016 Feb;20(2):145. doi: 10.5588/ijtld.15.0911. No abstract available.

PMID:
26792461
36.

Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants.

Odone A, Calderon R, Becerra MC, Zhang Z, Contreras CC, Yataco R, Galea J, Lecca L, Bonds MH, Mitnick CD, Murray MB.

PLoS One. 2016 Jan 14;11(1):e0146642. doi: 10.1371/journal.pone.0146642. eCollection 2016.

37.

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M.

J Clin Microbiol. 2016 Mar;54(3):727-33. doi: 10.1128/JCM.02775-15. Epub 2016 Jan 13.

38.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
39.

The need to accelerate access to new drugs for multidrug-resistant tuberculosis.

Cox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E.

Bull World Health Organ. 2015 Jul 1;93(7):491-7. doi: 10.2471/BLT.14.138925. Epub 2015 May 15.

40.

Risk factors for and origins of COPD.

Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB.

Lancet. 2015 May 2;385(9979):1723-1724. doi: 10.1016/S0140-6736(15)60884-4. No abstract available.

PMID:
25943930
41.

QTc prolongation and treatment of multidrug-resistant tuberculosis.

Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J.

Int J Tuberc Lung Dis. 2015 Apr;19(4):385-91. doi: 10.5588/ijtld.14.0335. Review.

PMID:
25859992
42.

Tuberculosis and chronic respiratory disease: a systematic review.

Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB.

Int J Infect Dis. 2015 Mar;32:138-46. doi: 10.1016/j.ijid.2014.12.016. Review.

43.

Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.

Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D.

Int J Infect Dis. 2015 Mar;32:56-60. doi: 10.1016/j.ijid.2014.12.012. Review.

44.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

45.

Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.

Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR.

Int J Tuberc Lung Dis. 2015 Mar;19(3):339-41. doi: 10.5588/ijtld.14.0814.

46.

Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.

Franke MF, Becerra MC, Tierney DB, Rich ML, Bonilla C, Bayona J, McLaughlin MM, Mitnick CD.

Ann Am Thorac Soc. 2015 May;12(5):674-9. doi: 10.1513/AnnalsATS.201411-538OC.

47.

Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment.

Tierney DB, Franke MF, Becerra MC, Alcántara Virú FA, Bonilla CA, Sánchez E, Guerra D, Muñoz M, Llaro K, Palacios E, Mestanza L, Hurtado RM, Furin JJ, Shin S, Mitnick CD.

PLoS One. 2014 Sep 19;9(9):e108035. doi: 10.1371/journal.pone.0108035. eCollection 2014.

48.

Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.

Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr.

Pain Med. 2014 Dec;15(12):2087-94. doi: 10.1111/pme.12520. Epub 2014 Sep 12.

PMID:
25220043
49.

Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.

Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S.

Clin Infect Dis. 2014 Jul 1;59(1):9-15. doi: 10.1093/cid/ciu209. Epub 2014 Apr 11.

50.

Principles for designing future regimens for multidrug-resistant tuberculosis.

Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR Jr, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M.

Bull World Health Organ. 2014 Jan 1;92(1):68-74. doi: 10.2471/BLT.13.122028. Epub 2013 Oct 25.

Supplemental Content

Loading ...
Support Center